Loading...
The drug known in the U.S. as ezogabine (internationally, retigabine), is a first-in-class agent for treating epilepsy by targeting neuron-specific voltage-gated potassium channels to dampen neuronal hyperexcitability. An earlier, placebo-controlled, dose-ranging study (Neurology 2007; 68:1197) indicated the agent's efficacy and safety. To confirm these findings, the current researchers conducted a manufacturer-funded, randomized, placebo-controlled trial of high-dose ezogabine (1200 mg/day) as adjunctive treatment for drug-resistant partial epilepsy in 305 patients.
The trial, called RESTORE 1, comprised an 8-week baseline phase, a 6-week titration phase, and a 12-week maintenance phase. The responder rate was defined as the percentage of p…